

1                                    **A pilot study of 0.4% povidone-iodine nasal spray to eradicate**  
2                                    **SARS-CoV-2 in the nasopharynx**

3 Rujipas Sirijatuphat<sup>1¶</sup>, Amorn Leelarasamee<sup>1,2\*</sup>, Thanapat Puangpet<sup>3¶</sup>, Arunee Thitithanyanont<sup>4¶</sup>

4  
5 <sup>1</sup>Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Thanon  
6 Wang Lang, Siriraj, Bangkoknoi, Bangkok 10700, Thailand

7 <sup>2</sup>Faculty of Medicine, Siam University, 38 Petchkasem Rd, Bang Wa, Phasi Charoen, Bangkok  
8 10160, Thailand

9 <sup>3</sup>Samut Sakhon Hospital, 1500 Ekkachai Rd, Tambon Mahachai, Mueang Samut Sakhon District,  
10 Samut Sakhon 74000, Thailand

11 <sup>4</sup>Department of Microbiology, Faculty of Science, Mahidol University, 272 Rama VI Road,  
12 Ratchathewi District, Bangkok 10400, Thailand

13  
14 **\*Corresponding author:**

15 E-mail: [amorn.lee@mahidol.ac.th](mailto:amorn.lee@mahidol.ac.th) (AL)

16  
17 <sup>¶</sup>These authors contributed equally to this work.

18 **Keywords**

19 Povidone iodine, nasal spray, COVID-19, SARS-CoV-2, viral eradication, viral culture,  
20 nasopharyngeal swab

21  
22 **Name of the registry and registration number:** Thai Clinical Trials Registry (TCTR) and  
23 registration id. TCTR20210125002.

24

25 **Abstract**

26 We studied the virucidal efficacy of 0.4% povidone-iodine (PVP-I) nasal spray against SARS-  
27 CoV-2 in the patients' nasopharynx at 3 minutes and 4 hours after PVP-I exposure. We used an  
28 open-label, before and after design, single arm pilot study of adult patients with RT-PCR-  
29 confirmed COVID-19 within 24 hours. All patients received three puffs of 0.4% PVP-I nasal  
30 spray in each nostril. Nasopharyngeal (NP) swabs were collected before the PVP-I spray  
31 (baseline, left NP samples), and at 3 minutes (left and right NP samples) and 4 hours post-PVP-I  
32 spray (right NP samples). All swabs were coded to blind assessors and transported to diagnostic  
33 laboratory and tested by RT-PCR and cultured to measure the viable SARS-CoV-2 within 24  
34 hours after collection. Fourteen patients were enrolled but viable SARS-CoV-2 was cultured  
35 from 12 patients (85.7%). The median viral titer at baseline was 3.5 log TCID<sub>50</sub>/mL (IQR 2.8-4.0  
36 log TCID<sub>50</sub>/mL). At 3 minutes post-PVP-I spray via the left nostril, viral titers were reduced in 8  
37 patients (66.7%). At 3 minutes post-PVP-I, the median viral titer was 3.4 log TCID<sub>50</sub>/mL (IQR  
38 1.8-4.4 log TCID<sub>50</sub>/mL) ( $P=0.162$ ). At 4 hours post-PVP-I spray via the right nostril, 6 of 11  
39 patients (54.5%) had either the same or minimal change in viral titers. The median viral titer 3  
40 minutes post-PVP-I spray was 2.7 log TCID<sub>50</sub>/mL (IQR 2.0-3.9 log TCID<sub>50</sub>/mL). Four hours  
41 post-PVP-I spray the median titer was 2.8 log TCID<sub>50</sub>/mL (IQR 2.2-3.9 log TCID<sub>50</sub>/mL)  
42 ( $P=0.704$ ). No adverse effects of 0.4% PVP-I nasal spray were detected. We concluded that  
43 0.4% PVP-I nasal spray demonstrated minimal virucidal efficacy at 3 minutes post-exposure. At  
44 4 hours post-exposure, the viral titer was considerably unchanged from baseline in 10 cases. The  
45 0.4% PVP-I nasal spray showed poor virucidal activity and is unlikely to reduce transmission of  
46 SARS-CoV-2 in prophylaxis use.

47

## 48 **Introduction**

49           Coronavirus disease 2019 (COVID-19) is an acute viral respiratory infection caused by  
50 the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that emerged in December  
51 2019 causing a pandemic that has killed millions [1]. The SARS-CoV-2 can persist in the upper  
52 respiratory tract of the patients at least seven days and spreads mainly via droplet and airborne  
53 transmission [2]. Patients are infectious for two to three days before the onset of symptoms, and  
54 are most contagious one to two days before the patients feel sick [3].

55           Povidone iodine (PVP-I) possesses rapid in-vitro virucidal activity against SARS-CoV-2  
56 [4-7]. It can reduce SARS-CoV-2 titers by approximately 100-fold within 30 seconds after PVP-I  
57 exposure [5]. It is a broad-spectrum antiseptic and used for topical application in skin solutions  
58 and throat sprays [8-10]. PVP-I has a good safety profile and is available in Thailand. We  
59 produce 0.4% PVP-I nasal spray and use to spray aerosols into nasal cavities and nasopharynx.  
60 The aerosols containing PVP-I will lay down easily on the mucosa in the turbinate and  
61 nasopharynx and exert PVP-I virucidal activity onsite. Nasal spray used by ordinary people is  
62 easy and more convenient than nasopharynx irrigation which needs to adjust head position and  
63 the patients has to hold breathing while performing irrigation to avoid suffocation.

64           We hypothesized that a nasal spray of PVP-I would decrease viable virus titers in the  
65 upper airway. One practice guideline advises the use of 0.4% PVP-I nasal application and 0.5%  
66 oropharyngeal application to reduce the risk of COVID-19 transmission [11]. However, evidence  
67 of in vivo efficacy against SARS-CoV-2 in humans is very limited. Two studies reported that  
68 PVP-I administration was associated with decreased SARS-CoV-2 titers in the oral cavity of

69 COVID-19 patients [12,13], while other studies have not demonstrated a virucidal effect of PVP-  
70 I in humans [14-16].

71 Therefore, we aimed to measure the speed of virucidal activity at three minutes and the  
72 sustainability of virucidal action at four hours after administration of a 0.4% PVP-I nasal spray in  
73 the patients with laboratory-confirmed COVID-19 infection. If the virucidal effect of PVP-I was  
74 rapid and at least 10 fold reduction from baseline was demonstrated in the patients' nasopharynx,  
75 it would be beneficial to public and healthcare professionals since PVP-I nasal spray would  
76 become a simple and cost-effective measure for preventing cross-contamination and community  
77 transmission of SARS-CoV-2.

78

## 79 **Materials and Methods**

80 This was an open-label, before and after study design, single-arm pilot study conducted  
81 from February 15, 2021 to March 15, 2021 at Siriraj Hospital and Samut Sakhon Hospital in  
82 Thailand and the patients were followed up for 24 hours in the hospital. The study protocol was  
83 approved by the Siriraj Institutional Review Board, Mahidol University, Thailand (COA.  
84 408/2020), and by the Ethic Committees of Samut Sakhon Hospital (SKH REC 10/2564/V.1).  
85 Written informed consent was obtained from all study participants. This study has been  
86 registered at Thai Clinical Trials Registry under registration id. TCTR20210125002. The authors  
87 confirmed that all ongoing trials for PVP-I were registered before the patient enrollment.

88 Eligible patients were adults aged 18-60 years with asymptomatic or mild disease due to  
89 SARS-CoV-2 with a cycle threshold (Ct) value less than 25 of either the N gene or ORF1ab by  
90 reverse transcriptase polymerase chain reaction (RT-PCR) in the 24 hours before study

91 enrollment. Patients with an iodine allergy or thyroid disease, pregnant or lactating women, and  
92 patients who had received antiviral agents (i.e., remdesivir and favipiravir) were excluded.

93 The 0.4% PVP-I was made by mixing 10% PVP-I solution with normal saline in 1:30  
94 ratio and used as nasal spray. The following intervention was performed sequentially in all  
95 patients; 1) specimen collection by nasopharyngeal (NP) swab via the left nostril (pre-exposure  
96 specimen), 2) administration of 0.4% PVP-I nasal spray via the left and right nostrils, 3) wait 3  
97 minutes and collect NP swab specimens through the left and right nostrils, 4) wait 4 hours and  
98 collect an NP swab specimen through the right nostril, 5) all participants were hospitalized to  
99 observe symptoms and side effects for at least 24 hours after the PVP-I nasal spray. All NP  
100 specimens were assigned numbers to blind laboratory technicians and kept in viral transport  
101 media (VTM) at 4 °C and sent to the microbiology laboratory for testing by RT-PCR and viral  
102 culture within 24 hours.

103 We planned to demonstrate the rapidity of 0.4% PVP-I antiviral activity by comparing  
104 the numbers of viral titer in the left side of nasopharynx (pre-exposure specimen) before and at 3  
105 minutes after PVP-I exposure. We also compared the average viral titer in the left side of  
106 nasopharynx (pre-exposure specimens) with that of the right side of nasopharynx at 3 minutes  
107 after PVP-I exposure to provide an additional information of virucidal speed assuming that the  
108 viral titers of the left and right sides of nasopharynx were equal before the PVP-I exposure. The  
109 sustainability of antiviral activity was evaluated by comparing the viral titers in the right side of  
110 nasopharynx at 3-minutes and 4-hours after PVP-I exposure.

111 RNA was extracted from 200 µL of viral transport media from the NP swab samples  
112 using MagDEA® Dx kit (Precision System Science, Chiba, Japan) and SARS-CoV-2 RT-PCR  
113 was performed by amplification of SARS-CoV-2 N and ORF1ab fragments using the Detection

114 Kit for 2019 Novel Coronavirus (2019-nCoV) RNA (PCR-Fluorescence Probing) (Da An Gene  
115 Co., Ltd. of Sun Yat-sen University, Guangdong, China), with a cycle threshold  $\leq 40$  considered  
116 positive [17]. For the viral culture test, titers were determined as the 50% tissue culture infective  
117 dose (TCID<sub>50</sub>) of the virus. Vero E6 cells expressing the type II transmembrane serine protease  
118 (Vero-TMPRSS2) [18] were seeded into 96-well plates and incubated with a serial dilution of the  
119 nasopharyngeal specimen. Cytopathic effects were evaluated daily until a 7-day incubation was  
120 completed.

121 Assuming that 70% of the pairs switch from the initial values of viable SARS-CoV-2  
122 counts in cell culture to less than 10 fold after 3 minute of PVP-I nasal exposure and 0% from  
123 the initial value to higher viable viral count after 3 minute of PVP-I nasal exposure, and after  
124 applying continuity correction, the pilot study would require a sample size of 10 pairs to achieve  
125 a power of 80% and a two sided significance of 5% for detecting a difference of -0.70 between  
126 the discordant proportions. [19]

127  
128 *Statistical analysis*

129 Demographic data were described with descriptive statistics. Quantitative data were  
130 described with mean  $\pm$  standard deviation, or median and interquartile range. Qualitative data  
131 were described in frequency (percent). The median of Ct value and viral titers were compared at  
132 each time point using the Wilcoxon signed-rank test and Mann-Whitney U test. A p value of  
133  $< 0.05$  was considered statistically significant.

134  
135 **Results**

136 Fourteen patients were enrolled and viable culture was obtained from 12 patients  
137 (85.7%). Six patients were male (50%) with a median age 34.0 years (interquartile range (IQR)  
138 27.5-45.0 years). Nine patients had mild disease and three patients had asymptomatic infection.  
139 The median duration from symptom onset to study enrollment was 3.0 days (IQR 1.5-4 days)  
140 (Table 1). No adverse events from PVP-I administration were observed during hospitalization.

141

142 Table 1. Demographic data of 12 patients with culturable NP samples

ID	Age range (years)	Sex	BMI (kg/m <sup>2</sup> )	Disease severity	Duration from symptom onset to enrollment (days)	TCID <sub>50</sub> /mL (baseline, left side of nasopharynx)
1	51-55	F	20.7	Mild	3	640
2	26-30	F	25.1	Mild	3	640
3	21-25	M	23.5	Mild	2	40,960
4	46-50	M	19.7	Mild	4	2,560
5	41-45	M	22.7	Asymptomatic	NA	10,240
6	41-45	F	20.1	Mild	1	10,240
7	41-45	M	23.5	Asymptomatic	NA	640
8	26-30	F	27.3	Mild	1	2,560
9	21-25	M	24.0	Mild	4	10,240
10	31-35	M	26.0	Asymptomatic	NA	5,120
11	26-30	F	26.4	Mild	3	40,960
12	36-40	F	41.4	Mild	4	640

143

144 Abbreviations: ID; identification number, F; female, M; male, NA; not applicable,

145 TCID<sub>50</sub>; median tissue culture infectious dose, NP; nasopharyngeal

146

147 At 3 minute post-PVP-I nasal spray eight of the 12 patients (66.7%) had a reduction of  
 148 viral titers. The median viral titer at baseline was 3.5 log TCID<sub>50</sub>/mL (IQR 2.8-4.0 log  
 149 TCID<sub>50</sub>/mL), and the median viral titer at 3 minute post-PVP-I exposure was 3.4 log TCID<sub>50</sub>/mL  
 150 (IQR 1.8-4.4 log TCID<sub>50</sub>/mL) ( $P=0.162$ ) (Tables 2 and 3). A median value of 0.1 log reduction  
 151 of viable viruses (IQR -0.05-0.23 log reduction) and 75.0% virus reduction (IQR -225.0%-  
 152 93.8%) were found. The median baseline Ct value of the N gene was 19.84 (IQR 17.77-21.52),  
 153 whereas the median Ct value of the N gene at 3 minute post-PVP-I was 19.49 (IQR 16.95-23.10)  
 154 ( $P=0.569$ ). The median baseline Ct value of the ORF1ab gene was 19.84 (IQR 16.82-22.22), and  
 155 the median Ct value of the ORF1ab gene at 3 minute post-PVP-I was 19.17 (IQR 15.81-24.87)  
 156 ( $P=0.469$ ).

157

158 Table 2. Cycle threshold (Ct) values for culturable NP samples

ID	N (baseline, Lt)	ORF1ab (baseline, Lt)	N (3 min, Lt)	ORF1ab (3 min, Lt)	N (3 min, Rt)	ORF1ab (3 min, Rt)	N (4 h, Rt)	ORF1ab (4 h, Rt)
1	21.96	23.00	25.42	26.52	23.44	24.61	21.93	22.91
2	22.64	24.18	23.99	25.45	20.71	22.34	24.47	26.12
3	19.71	21.31	21.54	23.13	19.32	20.62	20.41	21.68
4	20.73	20.14	20.18	21.47	19.79	21.16	19.96	21.29
5	17.73	19.00	18.54	19.83	19.74	21.09	22.23	23.49
6	18.45	19.53	19.23	18.08	18.69	19.87	18.20	19.32
7	20.40	22.52	23.62	26.22	21.49	23.63	21.27	23.10
8	19.96	18.46	19.10	17.72	17.03	15.72	18.21	16.91
9	16.19	15.08	16.42	15.17	17.36	16.29	17.94	16.61



10	17.89	16.27	16.39	15.07	15.73	14.50	16.76	15.39
11	16.30	15.20	15.40	14.36	19.41	18.23	16.91	15.83
12	21.78	20.38	19.75	18.51	24.40	23.30	24.68	23.47

159 Abbreviations: ID; identification number, Lt; left nasopharyngeal samples, Rt; right

160 nasopharyngeal samples, NP; nasopharyngeal

161

162 Table 3. Viral titers for culturable NP samples.

ID	TCID <sub>50</sub> /mL (baseline, Lt.)	TCID <sub>50</sub> /mL (3 min, Lt.)	TCID <sub>50</sub> /mL (3 min, Rt.)	TCID <sub>50</sub> /mL (4h, Rt.)
1	640	10	80	160
2	640	40	160	10
3	40960	2560	10240	10240
4	2560	40960	320	640
5	10240	5120	320	160
6	10240	1280	10240	1280
7	640	160	40	320
8	2560	2560	640	640
9	10240	40960	640	5120
10	5120	40960	40960	40960
11	40960	10240	2560	20480
12	640	40	0	0

163 Abbreviations: ID; identification number, Lt; left nasopharyngeal samples, Rt; right

164 nasopharyngeal samples, NP; nasopharyngeal

165  
166 The median viral titers of the left and right NP specimens at 3 minutes post-PVP-I  
167 exposure were 3.4 log TCID<sub>50</sub>/mL (IQR 1.8-4.4 log TCID<sub>50</sub>/mL) and 2.7 log TCID<sub>50</sub>/mL (IQR  
168 2.0-3.9 log TCID<sub>50</sub>/mL), respectively ( $P=0.433$ ). The median Ct value of the N gene of the left  
169 and right-side NP specimens at 3 minute post-PVP-I were 19.49 (IQR 16.95-23.10) and 19.58  
170 (IQR 17.69-21.30), respectively ( $P=0.977$ ). The median Ct value of the ORF1ab gene of the left  
171 and right-side NP specimens at 3 minute post-PVP-I were 19.17 (IQR 15.81-24.87) and 20.86  
172 (IQR 16.78-23.06), respectively ( $P=0.885$ ).

173 At 4 hour post-PVP-I nasal spray, six of the 11 patients (54.5%) were observed to have  
174 either the same titer or a minimal reduction of viral titers, and five patients had increased titers  
175 from the samples collected at 3 minute post-PVP-I. The median viral titer at 3 minute post-PVP-  
176 I exposure was 2.7 log TCID<sub>50</sub>/mL (IQR 2.0-3.9 log TCID<sub>50</sub>/mL), and the median viral titer at 4  
177 hour post-PVP-I exposure was 2.8 log TCID<sub>50</sub>/mL (IQR 2.2-3.9 log TCID<sub>50</sub>/mL) ( $P=0.704$ ). The  
178 median Ct value of the N gene at 3 minute post-PVP-I exposure was 19.58 (IQR 17.69-21.30),  
179 and the median Ct value of the N gene at 4 hour post-PVP-I exposure was 20.19 (IQR 18.01-  
180 22.16) ( $P=0.339$ ). The median Ct value of the ORF1ab gene at 3 minute post-PVP-I exposure  
181 was 20.86 (IQR 16.78-23.06), and the median Ct value of the ORF1ab gene at 4 hour post-PVP-I  
182 was 21.49 (IQR 16.69-23.38) ( $P=0.433$ ).

183  
184 Table 4. Change in viral titers after 3 minute and 4 hour exposure to PVP-I as compared to the  
185 baseline value from left NP specimens.

ID	≈ 10 fold	Within 4 fold reduction	No change or increase
----	-----------	-------------------------	-----------------------

	reduction		
1	3 min, Lt.	3 min, Rt.; 4h, Rt.	0
2	4h, Rt.	3 min, Lt.; 3 min, Rt.	0
3	0	3 min, Lt.; 3 min, Rt.; 4h, Rt.	0
4	0	3 min, Rt.; 4h, Rt.	3 min, Lt.
5	0	3 min, Lt.; 3 min, Lt; 4h, Rt.	0
6	0	3 min, Lt.; 4h, Rt.	3 min, Lt.
7	3 min Rt.	3 min, Lt.;4h, Rt.	
8	0	3 min, Rt.; 4h, Rt.	3 min, Lt.
9	0	3 min, Rt.; 4h, Rt.	3 min, Lt.
10	0	0	3 min, Lt.; 3 min, Lt.; 4h, Rt.
11	3 min, Rt.	3 min, Lt; 4h, Rt.	0
12	3 min, Lt.; 3 min, Rt.; 4h, Rt.	0	0

186

187

188

189

190

191

192

193

194

Only one case (no. 12) showed viral titers decreased approximately ten folds. The rest showed only within 1-4 fold reduction which could be due to sampling variation or weak PVP-I anti-viral activity. Five cases even had increased viral titers after PVP-I exposure. Overall, the decrease of viral titers is not rapid and not as much as shown by the in vitro test which is about 100 fold decrease 1 minute after PVP-I exposure. At 4 hour after PVP-I exposure, minimal or no change in viral titer was demonstrated. Overall, the PVP-I did not demonstrate rapid and strong virucidal activity as has been shown by the in vitro test.

## 195 Discussion

196 The TCID<sub>50</sub>/mL of the 12 patients with culturable NP samples varied from 640 to 40,960,  
197 which was not related to either disease severity or the onset of clinical symptoms when NP  
198 swabs were taken. Because all cases recovered uneventfully, the initial values of TCID<sub>50</sub>/ml did  
199 not predict the treatment outcome. However, the sample size was small and we did not plan to  
200 study the relationship between the initial viral titers and disease severity or clinical outcome.

201 We found a median one-fold reduction of SARS-CoV-2 viral titer from nasopharyngeal  
202 swabs at 3 minute post-PVP-I exposure in the left side of nasopharynx. This was in marked  
203 contrast to in vitro studies that reported as much as a 100-fold reduction in viral titer [5]. At 4  
204 hour post-exposure to 0.4% PVP-I nasal spray, the viral titer in the right side of nasopharynx was  
205 unchanged from baseline in 10 cases.

206 Although the in vitro rapid activity of PVP-I against SARS-CoV-2 has been established  
207 in several studies [5-7], evidence of in vivo activity in humans is limited. Two studies have  
208 reported that PVP-I administration into the upper aerodigestive tract of COVID-19 patients was  
209 associated with lower SARS-CoV-2 viral load and Ct values [12,13]. However, other studies  
210 have not confirmed their results [14-16]. To measure potential reductions in viral shedding, we  
211 believe that RT-PCR alone is insufficient and viral culture is needed. Using viral culture, PVP-I  
212 administration probably reduced infectious viral titers in the upper respiratory tract of COVID-19  
213 patients in two recent studies [20,21]. Friedland P et al demonstrated that 0.5% PVP-I nasal  
214 spray was associated with a reduction of viral titers in five of the six study participants (83%)  
215 five minutes after PVP-I application [20]. Seikai T et al revealed that gargling with PVP-I was  
216 associated with significantly decreased viral titers at 60 minutes after PVP-I exposure [20].

217 We found that PVP-I nasal spray had poor in vivo efficacy in our study. This could be  
218 explained by several factors including insufficient concentration, improper formulation and/or  
219 amount of PVP-I, inadequate duration of exposure, inappropriate method of administration, and  
220 mucociliary clearance of PVP-I from the nasal cavity [20]. We observed that 0.4% PVP-I nasal  
221 spray did not change the Ct value of the N and ORF1ab segments and did not interfere with  
222 PCR-mediated laboratory diagnosis of COVID-19. Finally, 0.4% PVP-I administered as a nasal  
223 spray was safe and well-tolerated.

224 Our study had some limitations. First, this was a small, single-arm, pre- and post-  
225 exposure pilot study, therefore, the study result may differ from larger-scale studies. Second, the  
226 study participants were likely infected with the strain B.1.36.16 of SARS-CoV-2 that caused  
227 infections in Thailand during the study period [22]. Our findings may not be generalizable to  
228 other variants of SARS-CoV-2.

229 However, since the PVP-I has been shown to exhibit broad-spectrum, rapid virucidal  
230 activity against various respiratory viruses by the in vitro tests, the finding of our study in  
231 patients infected with SARS-CoV-2 should give warning against its use for prophylaxis in  
232 ordinary people.

233

## 234 **Conclusions**

235 The 0.4% PVP-I nasal spray had minimal virucidal activity in the nasopharynx of  
236 infected patients. Hence, it is unlikely that this treatment would reduce airborne or droplet  
237 transmission of COVID-19. Other preventive measures such as vaccination, face masking, and  
238 personal protective equipment should be emphasized to limit COVID-19 transmission.

239

## 240 **Acknowledgements**

241 The authors gratefully acknowledge Mrs. Sukanya Chanboonchuay for her assistance with  
242 project management, Dr. Paraya Assanasen (ENT physician) for making the 0.4% PVP-I nasal  
243 spray, Miss Suwimon Manopwisedjaroen, M.Sc. and Miss Chanya Srisaowakarn, M.Sc. for  
244 microbiological laboratory assistance. The authors also thank the COVID-19 patient care team of  
245 Samut Sakhon Hospital (Mr. Chaiyot Ra-ngubpai, Miss Punyaneer Triamkan, Miss Laksamee  
246 Suddee, Miss Kitima Limprasert and Mrs. Walaiporn Jaiaree) for providing patient information,  
247 specimen collection, and patient observation during hospitalization.

248

## 249 **Declarations**

250 **Funding:** This work was supported by the Health Systems Research Institute (Thailand),  
251 Nonthaburi, Thailand; and, by the Faculty of Medicine Siriraj Hospital, Mahidol University,  
252 Bangkok, Thailand. The funders had no role in study design, data collection and analysis,  
253 decision to publish, or preparation of the manuscript.

254

255 **Competing Interests:** The authors declared that the research was conducted in the absence of  
256 any commercial or financial relationships that could be construed as a potential conflict of  
257 interest.

258

259 **Ethical Approval:** This study was approved by the Institutional Review Board of the Faculty of  
260 Medicine Siriraj Hospital, Mahidol University (COA. 408/2020), and by the ethic committees of  
261 Samut Sakhon Hospital (SKH REC 10/2564/V.1).

262

## 263 **References**

- 264 1. COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19  
265 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. *Lancet* 2022:S0140-  
266 6736(21)02796-3.
- 267 2. Badu K, Oyebola K, Zahouli JZB, Fagbamigbe AF, de Souza DK, et al. SARS-CoV-2 Viral  
268 Shedding and Transmission Dynamics: Implications of WHO COVID-19 Discharge Guidelines.  
269 *Front Med (Lausanne)* 2021;8:648660.
- 270 3. Casey-Bryars M, Griffin J, McAloon C, Byrne A, Madden J, Mc Evoy D, et al.  
271 Presymptomatic transmission of SARS-CoV-2 infection: a secondary analysis using published  
272 data. *BMJ Open* 2021;11:e041240.
- 273 4. Pelletier JS, Miller D, Liang B, Capriotti JA. In vitro efficacy of a povidone-iodine 0.4% and  
274 dexamethasone 0.1% suspension against ocular pathogens. *J Cataract Refract Surg* 2011; 37:  
275 763-766.
- 276 5. Anderson DE, Sivalingam V, Kang AEZ, Ananthanarayanan A, Arumugam H, Jenkins TM, et  
277 al. Povidone-iodine demonstrates rapid in vitro virucidal activity against SARS-CoV-2, the virus  
278 causing COVID-19 disease. *Infect Dis Ther* 2020; 9: 669-675.
- 279 6. Bidra AS, Pelletier JS, Westover JB, Frank S, Brown SM, Tessema B. Rapid In-Vitro  
280 Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Using  
281 Povidone-Iodine Oral Antiseptic Rinse. *J Prosthodont* 2020; 29: 529-533.
- 282 7. Shet M, Hong R, Igo D, Cataldo M, Bhaskar S. In vitro evaluation of the virucidal activity of  
283 different povidone-iodine formulations against murine and human coronaviruses. *Infect Dis Ther*  
284 2021; 10: 2777-2790.

- 285 8. Nagatake T, Ahmed K, Oishi K. Prevention of respiratory infections by povidone-iodine  
286 gargle. *Dermatology* 2002; 204 Suppl 1: 32-36.
- 287 9. Ghaddara HA, Kumar JA, Cadnum JL, Ng-Wong YK, Donskey CJ. Efficacy of a povidone  
288 iodine preparation in reducing nasal methicillin-resistant *Staphylococcus aureus* in colonized  
289 patients. *Am J Infect Control* 2020; 48: 456-459.
- 290 10. Peng HM, Wang LC, Zhai JL, Weng XS, Feng B, Wang W. Effectiveness of preoperative  
291 decolonization with nasal povidone iodine in Chinese patients undergoing elective orthopedic  
292 surgery: a prospective cross-sectional study. *Braz J Med Biol Res* 2017; 51: e6736.
- 293 11. Krajewska Wojciechowska J, Krajewski W, Zub K, Zatoński T. Review of practical  
294 recommendations for otolaryngologists and head and neck surgeons during the COVID-19  
295 pandemic. *Auris Nasus Larynx* 2020; 47: 544-558.
- 296 12. Seneviratne CJ, Balan P, Ko KKK, Udawatte NS, Lai D, Ng DHL, et al. Efficacy of  
297 commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in  
298 Singapore. *Infection* 2021; 49: 305-311.
- 299 13. Elzein R, Abdel-Sater F, Fakhreddine S, Hanna PA, Feghali R, Hamad H, et al. In vivo  
300 evaluation of the virucidal efficacy of Chlorhexidine and Povidone-iodine mouthwashes against  
301 salivary SARS-CoV-2. A randomized-controlled clinical trial. *J Evid Based Dent Pract* 2021; 21:  
302 101584.
- 303 14. Guenezan J, Garcia M, Strasters D, Jousselin C, Lévêque N, Frasca D, et al. Povidone iodine  
304 mouthwash, gargle, and nasal spray to reduce nasopharyngeal viral load in patients with COVID-  
305 19: A randomized clinical trial. *JAMA Otolaryngol Head Neck Surg* 2021; 147: 400-401.



- 306 15. Zarabanda D, Vukkadala N, Phillips KM, Qian ZJ, Mfuh KO, Hatter MJ, et al. The Effect of  
307 Povidone-Iodine Nasal Spray on Nasopharyngeal SARS-CoV-2 Viral Load: A Randomized  
308 Control Trial. *Laryngoscope* 2021; 10.1002/lary.29935.
- 309 16. Ferrer MD, Barrueco AS, Martinez-Beneyto Y, Mateos-Moreno MV, Ausina-Márquez V,  
310 García-Vázquez E, et al. Clinical evaluation of antiseptic mouth rinses to reduce salivary load of  
311 SARS-CoV-2. *Sci Rep* 2021; 11: 24392.
- 312 17. A R, Wang H, Wang W, Tan W. Summary of the Detection Kits for SARS-CoV-2  
313 Approved by the National Medical Products Administration of China and Their Application for  
314 Diagnosis of COVID-19. *Virology* 2020; 35: 699-712.
- 315 18. Sasaki M, Uemura K, Sato A, Toba S, Sanaki T, Maenaka K, et al. SARS-CoV-2 variants  
316 with mutations at the S1/S2 cleavage site are generated in vitro during propagation in  
317 TMPRSS2-deficient cells. *PLoS Pathog* 2021; 17: e1009233.
- 318 19. Dhand NK, Khatkar MS. (2014). Statulator: An online statistical calculator. Sample Size  
319 Calculator for Comparing Two Paired Proportions. Accessed 25 July 2022 at  
320 <http://statulator.com/SampleSize/ss2PP.html>
- 321 20. Friedland P, Tucker S, Goodall S, Julander J, Meddenhall M, Molloy P, et al. In vivo  
322 (human) and in vitro inactivation of SARS-CoV-2 with 0.5% povidone-iodine nasal spray. *Aust*  
323 *J Otolaryngol* 2022; 5: 2.
- 324 21. Seikai T, Takada A, Hasebe A, Kajihara M, Okuya K, Sekiguchi Yamada T, et al. Gargling  
325 with povidone iodine has a short-term inhibitory effect on SARS-CoV-2 in patients with  
326 COVID-19. *J Hosp Infect* 2022: S0195-6701(22)00006-8.

- 327 22. Kunno J, Supawattanabodee B, Sumanasrethakul C, Wiriyasivaj B, Kuratong S,  
328 Kaewchandee C. Comparison of Different Waves during the COVID-19 Pandemic:  
329 Retrospective Descriptive Study in Thailand. *Adv Prev Med* 2021; 2021: 5807056.